Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Revenue Recognized by Revenue Source

The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2021 and 2020 (in thousands):

Revenue Recognition

	December 31,
	2021		2020
Pharmaceutical Development Segment
License Agreement	$	15,871	$	5,827
Pharmaceutical development and other		974		76
Total contract revenue	$	16,845	$	5,903

Schedule of Company's Contract Liabilities

The Company’s contract liabilities are presented as deferred revenues and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):

Revenue Recognition (Details 2)

	December 31,
	2021		2020
Pharmaceutical Development Segment
Deferred revenue	$	185	$	350
Total contract liabilities	$	185	$	350